Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC Haplo-BM Transplant for Hematologic Diseases
NCT02145039Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Oct 2014
- Primary completion
- Jan 2018
- Countries
- 1
01
Overview
Open-label, single-arm trial in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and 14 more, sponsored by Masonic Cancer Center. Primary endpoint: 2 Year Survival. Started Oct 2014; status: terminated.
02
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)Burkitt lymphoma (BL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02145039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145039.